Autoimmune blistering diseases (AIBDs) are a group of dermatological conditions characterized by loss of immunotolerance and humoral, as well as cellular, autoimmune responses that result in the development of bullae and erosions on the skin and mucous membranes. AIBDs represent a challenge in terms of understanding the underlying etiopathogenesis and in terms of therapeutic approaches. For decades no truly significant advance in the treatment of AIBDs has been made. However, in recent years new therapeutic approaches have been investigated. Some did not provide satisfactory results but others were found to be very promising. Many of these newly investigated approaches derive from a better understanding of the pathogenesis of AIBDs and were designed as targeted therapies. Advances in AIBDs management should be focused on shifting the therapeutic paradigm from a broad-spectrum immune suppression to a selective inhibition of altered pathways. Translational medicine may represent the key to discovering new therapeutic approaches for AIBDs.
This special issue was ideated with the goal of collecting and highlighting the most recent and cutting-edge research on the pathogenesis of AIBDs and to collect evidence of recent therapeutic approaches.
The type of manuscripts we are looking for comprise: original articles, brief research reports, systematic reviews, reviews, mini reviews, commentaries, case reports, case series, and clinical trials.
Autoimmune blistering diseases (AIBDs) are a group of dermatological conditions characterized by loss of immunotolerance and humoral, as well as cellular, autoimmune responses that result in the development of bullae and erosions on the skin and mucous membranes. AIBDs represent a challenge in terms of understanding the underlying etiopathogenesis and in terms of therapeutic approaches. For decades no truly significant advance in the treatment of AIBDs has been made. However, in recent years new therapeutic approaches have been investigated. Some did not provide satisfactory results but others were found to be very promising. Many of these newly investigated approaches derive from a better understanding of the pathogenesis of AIBDs and were designed as targeted therapies. Advances in AIBDs management should be focused on shifting the therapeutic paradigm from a broad-spectrum immune suppression to a selective inhibition of altered pathways. Translational medicine may represent the key to discovering new therapeutic approaches for AIBDs.
This special issue was ideated with the goal of collecting and highlighting the most recent and cutting-edge research on the pathogenesis of AIBDs and to collect evidence of recent therapeutic approaches.
The type of manuscripts we are looking for comprise: original articles, brief research reports, systematic reviews, reviews, mini reviews, commentaries, case reports, case series, and clinical trials.
